雷贝拉唑钠与多潘立酮联合熊去氧胆酸治疗胆汁反流性食管炎效果观察

目的 探讨雷贝拉唑钠与多潘立酮联合熊去氧胆酸治疗胆汁反流性食管炎的临床效果.方法 将97例胆汁反流性食管炎患者完全随机分为2组：观察组55例,应用多潘立酮10 mg/次,3次/d口服治疗,雷贝拉唑肠溶片20 mg/次,2次/d,熊去氧胆酸250 mg/次,2次/d口服治疗;对照组42例,应用多潘立酮10 mg/次,3次/d,雷贝拉唑肠溶片20 mg/次,2次/d口服治疗;2组均治疗4周.之后复查内镜,检查食管黏膜情况.结果 观察组患者治疗前及治疗后第1、4周烧心积分分别为（3.1±2.1）、（0.9±0.3）、（0.3±0.1）分,反酸积分分别为（3.2±1.7）、（0.9±0.2）、（0.4±0.2）分,胸痛积分分别为（3.5±1.2）、（0.9±0.3）、（0.3±0.1）分,治疗后第1、4周症状积分均明显降低（均P＜0.01）.对照组患者治疗前及治疗后第1、4周烧心积分分别为（3.3±0.7）、（2.1±1.2）、（1.7±0.8）分,反酸积分分别为（3.4±1.4）、（2.3±1.1）、（1.7±0.3）分,胸痛积分分别为（3.4±1.1）、（2.4±1.2）、（1.9±0.5）分,治疗后症状积分较治疗前也有降低（P＜0.05）.内镜检查观察组治愈率85.5％（47/55）,有效率98.2％（54/55）;对照组治愈率40.5％ （17/42）,有效率54.8％（23/42）.2组治愈率及有效率比较差异均有统计学意义（均P＜0.05）.结论 雷贝拉唑钠与多潘立酮联合熊去氧胆酸治疗胆汁反流性食管炎疗效确切.

Effect of rabeprazole and domperidone combining ursodesoxycholic acid on bile reflux esophagitis

Objective To investigate the effect of rabeprazole and domperidone combining ursodesoxycholic acid（UDCA） in the treatment of bile reflux esophagitis.Methods Totally 97 patients were divided into 2 groups randomly,55 cases in observation group （dosage regimen：domperidone 30 mg per day,divide into three times,uursodesoxycholic acid 500 mg per day,divide into two times; rabeprazole 40 mg per day,divide into two times.All for four weeks）,and 42 cases in control group （dosage regimen：domperidone 30 mg per day,divide into three times.rabeprazole 40 mg per day,divide into two times,for four weeks）.All patients had gastroscope again when complishing the treatment,the condition of esophageal mucosa were chocked.Results In observation group,the symptoms integral was significantly reduced after treatment for 1 week heartburn integral（0.9 ±0.8）,reflux integral （0.9 ± 0.8）,chest pain integral （0.9 ± 0.3）,after treatment for 4 weeks heartburn integral （0.3 ± 0.1）,reflux integral （0.4 ± 0.2）,chest pain integral （0.3 ± 0.1）] （P ＜ 0.01） on the forth treatment week compaired with the first week,but the control group reduce lessafter treatment for 1 week heartburn integral （2.1 ± 1.2）,reflux integral （2.3 ± 1.1）,chest pain integral （2.4 ± 1.2）,after treatment for 4 weeks heartburn integral （1.7 ± 0.8）,refluxintegral （1.7 ± 0.3）,chest pain integral （1.9 ± 0.5）] （P ＜ 0.05）.The cure rate and effective rate were 74.2％ and 96.8％ respectively in observation group,and 46.8％ and 53.3％ in control group,via gastroscope check.Conclusion The effect of UDCA in the treatment of bile reflux esophagitis is reliable.